Cyclosporine (Huons)(Cyclosporine (Huons)) - 药物靶点：CaN_在研适应症：干眼症_专利_临床

概要

基本信息

药物类型

合成多肽

别名

Ciclosporin (Huons)、Clacier

+ [2]

靶点

CaN

作用方式

抑制剂

作用机制

CaN抑制剂(钙神经素抑制剂)

治疗领域

眼部疾病

在研适应症

干眼症

非在研适应症-

原研机构

Huons Co., Ltd.

在研机构

Huons Co., Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

韩国 (2018-11-26),

干眼症

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C62H111N11O12

InChIKeyPMATZTZNYRCHOR-CGLBZJNRSA-N

CAS号59865-13-3

关联

15

项与 Cyclosporine (Huons) 相关的临床试验

CTRI/2023/03/050453

/ Not yet recruiting临床3期IIT

A prospective randomised study comparing the efficacy and safety of oral cyclosporine versus oral steroids in the management of refractory cases of oral lichen planus

开始日期2023-03-16

申办/合作机构-

NCT05057468

/ Unknown status临床3期IIT

Cyclosporine as a Second-line Treatment of Primary Autoimmune Hemolytic Anemia

the cyclosporine showed efficacy in many immune cytopenic diseases in the light of numerous case reports and retrospective data. This study compares cyclosporin versus rituximab in steroid-refractory anemia.

开始日期2021-10-20

申办/合作机构

Assiut University

NCT04412785

/ Completed临床1期IIT

Phase I Trial for the Prevention of Cytokine Release Syndrome (CRS) With Cyclosporine in Patients With Moderate COVID-19

Phase 1 safety study to determine the tolerability, clinical effects, and changes in laboratory parameters of short course oral or IV cyclosporine (CSA) administration in patients with COVID-19 disease requiring oxygen supplementation but not requiring ventilator support.

开始日期2020-06-30

申办/合作机构

University of Pennsylvania

100 项与 Cyclosporine (Huons) 相关的临床结果

登录后查看更多信息

100 项与 Cyclosporine (Huons) 相关的转化医学

登录后查看更多信息

100 项与 Cyclosporine (Huons) 相关的专利（医药）

登录后查看更多信息

31,620

项与 Cyclosporine (Huons) 相关的文献（医药）

2025-02-01·Food Chemistry

Taste characterization and molecular docking study of novel umami flavor peptides in Yanjin black bone Chicken meat

Article

作者: Zhao, Ping ; Yang, Chaohui ; Ge, Changrong ; Ge, Xuehai ; Xiao, Zhichao ; Liang, Shuangmin

Five polypeptides with a potential umami taste were isolated and purified from Yanjin black bone chicken. However, the flavor characteristics and umami mechanism have not been clarified. The umami properties of these five peptides were investigated in this work using a range of analytical techniques, computer simulation, and sensory evaluation. HE-10 and TP-7 exhibited the strongest umami flavors. Furthermore, dose-response experiments showed that the umami peptides enhanced umami by generating peptide mineral chelates. Environmental scanning electron microscopy (ESEM) microstructural analyses supported this finding. The molecular docking results indicated that the five polypeptides bind to four critical amino acid residues, namely Glu217, Glu148, Asp216, and His145, of the T1R1/T1R3 receptor. The binding occurred through van der Waals, electrostatic interactions, hydrogen bonding, and hydrophobic interactions. The main surface forces implicated include aromatic interactions, hydrogen bonding, hydrophilicity, and solvent accessibility.

2024-12-31·Renal Failure

Clinicopathological characteristics and outcomes of PLA2R related idiopathic membranous nephropathy in patients with seronegative PLA2R antibodies

Article

作者: Li, Yanchun ; Shen, Yang ; Ma, Lijie ; Sun, Qianmei ; Li, Xue

BACKGROUNDIdiopathic membranous nephropathy (IMN) with deposits of phospholipase A2 receptor (PLA2R) antigen in glomerular tissue (GAg+) but no circulating serum PLA2R antibody (SAb-) has been reported. However, little is known about the clinicopathological characteristics and prognosis of this subtype.METHODSA total of 74 IMN patients with GAg + identified by kidney biopsy were enrolled in this study. We categorized patients into two groups based on the presence or absence of serum PLA2R antibody. Data on clinical features, pathological features, and outcomes were collected. Kaplan-Meier analysis of complete remission (CR) and partial remission (PR) comparing SAb-/GAg + and SAb+/GAg + patients. Cox proportional hazards models was used to examine factors associated with CR and PR.RESULTSAmong 74 IMN patients, 14 were SAb-/GAg+. Compared with SAb+/GAg + patients, SAb-/GAg + patients presented with higher levels of albumin, lower levels of cholesterol and low density lipoprotein cholesterol (all p < .01), but similar pathological manifestations of kidney biopsy. Multivariate logistic analyses indicated that low albumin (0.79 [95%CI: 0.66-0.95], p = .01) and high cholesterol (1.81 [95%CI: 1.02-3.19], p = .04) were correlated with seropositivity of PLA2R antibody. SAb-/GAg + patients exhibited a significantly higher probability of CR (p = .03) than patients who were SAb+/GAg+. However, no difference was found in the PR rate. Cox regression analyses showed that compared to SAb+/GAg + patients, SAb-/GAg + was more predictive of complete remission (4.28 [95%CI: 1.01-18.17], p = .04).CONCLUSIONIMN with PLA2R staining on kidney biopsy but without serum PLA2R antibody has milder clinical manifestations and a better prognosis.

2024-12-31·Hematology

High- vs regular-dose recombinant human thrombopoietin plus cyclosporine A in patients with newly diagnosed non-severe aplastic anemia: a retrospective cohort study

Article

作者: Yang, Yuan ; Han, Bing ; Chen, Miao ; Yang, Chen ; Hu, Qinglin

BACKGROUNDCyclosporine A (CsA) and regular doses of recombinant human thrombopoietin (rhTPO) can accelerate platelet recovery in patients with non-severe aplastic anemia (NSAA). However, it is unclear whether CsA plus rhTPO at a higher dose can further increase the efficacy.METHODSData from patients with newly diagnosed NSAA, who had been treated with CsA in combination with different doses of rhTPO between February 2021 and August 2021 at Peking Union Medical College Hospital, were reviewed. All the enrolled patients had been treated with CsA at 3-5 mg/(kg/d), and patients were further classified into high-dose (with rhTPO 30000U qd × 14 days for 2 months) group or regular-dose (with rhTPO 15000U qd × 7days for 3 months) group. The treatment response and therapy-related adverse events were compared.RESULTS36 patients including 16 (44.4%) in the high-dose and 20 (55.6%) in the regular-dose group were enrolled. The baseline characteristics were compatible between the two groups. The platelet counts were significantly higher at 1/3/6 months in the high-dose group (p = 0.028, 0.0063 and p = 0.040, respectively). The high-dose group had a significantly shorter time to platelet transfusion independence ([1 (0.5-6) months vs 2.5 (1-12) months, p = 0.040]). There was no significant difference in overall response and complete response rate between the two groups at 1/3/6/12 months (p > 0.05). Treatment-related morbidities were similar between the two groups (p > 0.05).CONCLUSIONSAdding a higher dose of rhTPO can further accelerate platelet recovery and platelet transfusion independence in patients with newly diagnosed NSAA.

100 项与 Cyclosporine (Huons) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB00091

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
干眼症	韩国	Huons Co., Ltd.	2018-11-26

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
干眼综合征	药物发现	-	Huons Co., Ltd.	2013-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00987480 (CTgov)	临床2期	白血病 \| 骨髓增生异常综合征 \| 范可尼贫血	45	CliniMACS device+fludarabine+Busulfan+cyclosporine.+cyclophosphamide	顧選鹹製糧壓齋簾願獵(觸構簾選遞夢簾齋糧衊) = 衊蓋顧襯鏇選觸願遞願遞蓋鹽餘繭糧襯窪鹽觸 (艱糧觸獵網廠鹽獵積餘, 夢遞製簾齋鑰築蓋範網 ~ 膚顧壓廠鬱鬱顧築蓋顧) 更多	-	2018-07-10
NCT00974142 (CTgov)	临床1/2期	慢性阻塞性肺疾病	43	Cyclosporine (Cyclosporine)	蓋獵願製壓觸窪築襯範(衊願獵襯夢淵鹹艱廠衊) = 築繭齋鹹鬱襯鬱繭鑰繭簾齋襯遞膚網製醖淵艱 (壓鹽襯鬱廠膚衊構獵醖, 願獵壓醖網廠夢糧壓窪 ~ 遞選醖廠願壓觸鬱築觸) 更多	-	2018-05-09
				Placebo (Placebo)	蓋獵願製壓觸窪築襯範(衊願獵襯夢淵鹹艱廠衊) = 膚簾襯構衊鬱蓋築淵顧簾齋襯遞膚網製醖淵艱 (壓鹽襯鬱廠膚衊構獵醖, 積膚鹽遞鹽鹽窪壓鹹繭 ~ 艱積簾鬱襯鏇餘夢淵衊) 更多
NCT00609739 (CTgov)	临床1/2期	幼年型骨髓单核细胞白血病	1	umbilical cord blood transplantation+methylprednisolone+Cis-Retinoic acid+cyclosporine+Filgrastim+mitoxantrone hydrochloride+methotrexate+Cytarabine	(網鹽網製窪蓋觸醖齋餘) = 鏇願構醖遞鏇範淵醖糧糧淵襯膚構糧願壓壓築 (艱鹹鹹膚蓋遞醖製淵積, 醖膚夢鹹襯鏇憲繭蓋餘 ~ 顧蓋鹹餘遞襯獵鹽積廠) 更多	-	2012-03-02
NCT00154284 (CERTES02, CTgov)	临床3期	肾移植排斥反应	114	Steroid+Cyclosporine (Neoral)+Basiliximab (Simulect)+Everolimus (Certican) (Everolimus (Certican) With Cyclosporine (Neoral) Continuation)	鹽願積鬱蓋醖廠糧壓觸(鑰壓遞顧膚醖繭繭構構) = 遞鑰餘製遞繭繭顧蓋觸壓鏇衊窪蓋鹽壓窪醖襯 (繭網醖鬱醖廠膚膚選獵, 網衊膚鹹鹽鬱糧鹹衊醖 ~ 範窪築壓鏇鹹積積鹹蓋) 更多	-	2011-03-11
				Steroid+Cyclosporine (Neoral)+Basiliximab (Simulect)+Everolimus (Certican) (Everolimus (Certican) With Cyclosporine (Neoral) Withdrawal)	鹽願積鬱蓋醖廠糧壓觸(鑰壓遞顧膚醖繭繭構構) = 壓鏇獵顧餘願衊構觸願壓鏇衊窪蓋鹽壓窪醖襯 (繭網醖鬱醖廠膚膚選獵, 願範糧網淵艱廠遞遞鏇 ~ 憲鏇鏇築觸鏇繭鏇範鬱) 更多
NCT00419926 (CTgov)	临床4期	-	313	Cyclosporine (Neoral)+Prednisone+Enteric-coated mycophenolate sodium (Myfortic) (Intensified Mycophenolate Sodium (Myfortic) Dosing Regimen)	蓋製願構選糧夢構衊醖(築窪顧願醖鑰糧夢簾壓) = 網鹹壓廠選鹹壓鬱衊範鏇壓衊顧構憲齋鑰鏇顧 (淵鏇壓廠蓋糧觸鑰顧積, 蓋壓衊願餘壓築艱觸憲 ~ 膚蓋鏇廠獵壓築膚窪築) 更多	-	2011-01-11
				Cyclosporine (Neoral)+Prednisone+Enteric-coated mycophenolate sodium (Myfortic) (Standard Mycophenolate Sodium (Myfortic) Dosing Regimen)	蓋製願構選糧夢構衊醖(築窪顧願醖鑰糧夢簾壓) = 淵築繭壓願窪鑰願遞製鏇壓衊顧構憲齋鑰鏇顧 (淵鏇壓廠蓋糧觸鑰顧積, 遞壓窪窪範憲齋繭遞艱 ~ 蓋壓選壓網觸鬱製願窪) 更多